About ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-based biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio1.00%
Current Ratio6.69%
Quick Ratio5.35%
Price-To-Earnings
Trailing P/E Ratio-2.52
Forward P/E Ratio-3.63
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales9.84
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book5.55
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-58.67%
Return on Equity-75.62%
Return on Assets-18.77%
Miscellaneous
Employees295
Outstanding Shares45,320,000
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics (NASDAQ:ADMA) issued its quarterly earnings data on Monday, March, 5th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.27. The biotechnology company had revenue of $12 million for the quarter, compared to analysts' expectations of $6.68 million. ADMA Biologics had a negative return on equity of 75.62% and a negative net margin of 58.67%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
2 brokerages have issued 1 year price objectives for ADMA Biologics' stock. Their predictions range from $5.00 to $8.00. On average, they expect ADMA Biologics' stock price to reach $6.50 in the next twelve months. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Agenus (AGEN), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA), Solid Biosciences (SLDB), Cellular Biomedicine (CBMG), Adverum Biotechnologies (ADVM), NantKwest (NK), Allena Pharmaceuticals (ALNA), Fennec Pharmaceuticals (FENC), Osiris Therapeutics (OSIR), NanoString Technologies (NSTG), Arsanis (ASNS), Compugen (CGEN), Pluristem Therapeutics (PSTI), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Lorus Therapeutics (APTO) and Curis (CRIS).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz CPA, VP, CFO & Principal Accounting Officer (Age 46)
- Dr. James Mond M.D., Ph.D., Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Has ADMA Biologics been receiving favorable news coverage?
Media headlines about ADMA stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ADMA Biologics earned a media sentiment score of 0.17 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.94.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $213.90 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
ADMA Biologics (NASDAQ:ADMA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for ADMA Biologics in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 31.58%. The high price target for ADMA is $8.00 and the low price target for ADMA is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.50 | $6.50 | $6.50 | $13.00 |
| Price Target Upside: | 31.58% upside | 69.27% upside | 135.51% upside | 220.20% upside |
ADMA Biologics (NASDAQ:ADMA) Consensus Price Target History
ADMA Biologics (NASDAQ:ADMA) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/5/2018 | Maxim Group | Set Price Target | Buy | $8.00 | High |  |
| 11/14/2017 | Raymond James | Upgrade | Market Perform -> Outperform | $5.00 | N/A | |
(Data available from 4/20/2016 forward)
ADMA Biologics (NASDAQ:ADMA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ADMA Biologics (NASDAQ ADMA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 37.58%
ADMA Biologics (NASDAQ ADMA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/9/2017 | Adam S Grossman | Insider | Buy | 485,000 | $2.15 | $1,042,750.00 | | |
| 11/9/2017 | Brian Lenz | CFO | Buy | 6,500 | $2.15 | $13,975.00 | 15,000 | |
| 11/9/2017 | Eric I Richman | Director | Buy | 25,000 | $2.15 | $53,750.00 | 31,300 | |
| 11/9/2017 | James Mond | CMO | Buy | 10,000 | $2.15 | $21,500.00 | 13,389 | |
| 5/3/2016 | Adam S Grossman | CEO | Buy | 200,000 | $6.50 | $1,300,000.00 | | |
| 5/3/2016 | Brian Lenz | CFO | Buy | 2,500 | $6.50 | $16,250.00 | 8,500 | |
| 5/3/2016 | James Mond | CMO | Buy | 770 | $6.50 | $5,005.00 | 3,389 | |
| 5/3/2016 | Jerrold B Grossman | Director | Buy | 45,769 | $6.50 | $297,498.50 | | |
| 12/8/2015 | Adam S. Grossman | CEO | Buy | 500 | $9.00 | $4,500.00 | 637,268 | |
| 12/7/2015 | Jerrold B Grossman | Director | Buy | 500 | $9.01 | $4,505.00 | 56,558 | |
| 12/2/2015 | Adam S Grossman | CEO | Buy | 2,250 | $9.15 | $20,587.50 | 636,768 | |
| 12/2/2015 | Brian Lenz | CFO | Buy | 1,000 | $9.15 | $9,150.00 | 6,000 | |
| 12/2/2015 | Jerrold B Grossman | Director | Buy | 6,000 | $9.16 | $54,960.00 | 56,058 | |
| 12/1/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.17 | $16,506.00 | | |
| 11/25/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.18 | $16,524.00 | | |
| 11/20/2015 | Adam S Grossman | CEO | Buy | 3,861 | $9.21 | $35,559.81 | 628,418 | |
| 3/19/2015 | Adam S Grossman | CEO | Buy | 2,000 | $8.50 | $17,000.00 | | |
| 3/17/2015 | Adam S Grossman | CEO | Buy | 5,500 | $7.98 | $43,890.00 | | |
| 3/17/2015 | Jerrold B Grossman | Director | Buy | 500 | $8.01 | $4,005.00 | | |
| 3/16/2015 | Adam S Grossman | CEO | Buy | 8,800 | $8.03 | $70,664.00 | | |
| 3/16/2015 | James Mond | CMO | Buy | 1,250 | $8.02 | $10,025.00 | | |
| 3/16/2015 | Lawrence P Guiheen | Director | Buy | 1,000 | $7.96 | $7,960.00 | | |
| 3/13/2015 | Eric I Richman | Director | Buy | 3,500 | $7.88 | $27,580.00 | | |
| 9/12/2014 | Adam S Grossman | CEO | Buy | 4,300 | $9.57 | $41,151.00 | | |
| 8/22/2014 | Adam S Grossman | CEO | Buy | 1,000 | $9.50 | $9,500.00 | | |
| 8/14/2014 | Adam S Grossman | CEO | Buy | 2,100 | $9.77 | $20,517.00 | | |
| 6/18/2014 | Adam S Grossman | CEO | Buy | 1,875 | $9.59 | $17,981.25 | | |
| 5/22/2014 | Adam S Grossman | CEO | Buy | 4,226 | $8.15 | $34,441.90 | | |
| 5/15/2014 | Adam S Grossman | CEO | Buy | 13,400 | $7.50 | $100,500.00 | | |
| 5/14/2014 | Brian Lenz | CFO | Buy | 1,000 | $7.50 | $7,500.00 | | |
| 5/14/2014 | James Mond | CMO | Buy | 1,315 | $7.60 | $9,994.00 | | |
| 12/10/2013 | Jerrold B Grossman | Director | Buy | 3,650 | $7.30 | $26,645.00 | | |
(Data available from 1/1/2013 forward)
ADMA Biologics (NASDAQ ADMA) News Headlines
| Source: |
|
ADMA Biologics (NASDAQ:ADMA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ADMA Biologics (NASDAQ:ADMA) Income Statement, Balance Sheet and Cash Flow Statement
ADMA Biologics (NASDAQ ADMA) Stock Chart for Friday, April, 20, 2018
Loading chart…
